pH-Sensitive nanoparticles: An effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs

Pharmaceutical Research

Volumn 13, Issue 3, 1996, Pages 485-487

  Leroux, Jean Christophe ^a   Cozens, Robert M ^b   Roesel, Johannes L ^b   Galli, Bruno ^b   Doelker, Eric ^a   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Pharma Research   (Switzerland)

Author keywords

Dog AIDS treatment; HIV protease inhibitor; Methacrylic acid copolymer; Nanoparticle; Solid dispersion

Indexed keywords

ANTIVIRUS AGENT; CGP 57813; COPOLYMER; EUDRAGIT; EUDRAGIT RS; NANOPARTICLE; POLYMER; POLYMETHACRYLIC ACID; POLYVINYL ALCOHOL; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISPERSION; DOG; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PH; PHARMACOKINETICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; DOGS; EVALUATION STUDIES; FEMALE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HYDROGEN-ION CONCENTRATION; INTESTINES; MALE; OLIGOPEPTIDES; PARTICLE SIZE; SENSITIVITY AND SPECIFICITY;

EID: 0029962749     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016073416332     Document Type: Article

References (11)

1. M. Lang and J. Roesel. HIV-1 protease inhibitors: development, status, and potential role in the treatment of AIDS. Arch. Pharm. 326:921-924 (1993).
2. S. S. Abdel-Meguid, B. W. Metcalf, T. J. Carr, P. Demarsh, R. L. DesJarlais, S. Fisher, D. W. Green, L. Ivanoff, D. M. Lambert, K. H. M. Murthy, S. R. Petteway Jr., W. J. Pitts, T. A. Tomaszek Jr., E. Winborne, B. Zhao, G. B. Dreyer and T. D. Meek. An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and Pharmacokinetic analysis, Biochemistry 33:11671-11677 (1994).
3. J. C. Leroux, R. Cozens, J. L. Roesel, B. Galli, F. Kubel, E. Doelker and R. Gurny. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J. Pharm. Sci. 84:1387-1391 (1995).
4. E. Allémann, E. Doelker and R. Gurny. Drug loaded poly(lactic acid) nanoparticles produced by a reversible salting-out process: purification of an injectable dosage form. Eur. J. Pharm. Biopharm. 39:13-18 (1993).
5. J. C. Leroux, F. De Jaeghere, B. Anner, E. Doelker and R. Gurny. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D, L-lactic acid) nanoparticles by human monocytes. Life Sci. 57:695-703 (1995).
6. E. Alteri, G. Bold, R. Cozens, A. Faessler, T. Klimkait, M. Lang, J. Lazdins, B. Poncioni, J. L. Roesel, P. Schneider, M. Walker and K. Woods-Cook. CGP 57813, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob. Agents Chemother. 37:2087-2092 (1993).
7. C. Verdun, P. Couvreur, H. Vranckx, V. Lenaerts and M. Roland. Development of a nanoparticle controlled-release formulation. J. Controlled Release 3:205-210 (1986).
8. F. R. Gabler. Principles of tangential flow filtration: applications to biological processing. In T. H. Meltzer, Filtration in the Pharmaceutical Industry, Marcel Dekker, New York, 1987, pp. 453-490.
9. F. Chouinard, F. W. K. Kan, J. C. Leroux, C. Foucher and V. Lenaerts. Preparation and purification of polyisohexylcyanoacrylate nanocapsules. Int. J. Pharm. 72:211-217 (1991).
10. A. de Labouret, O. Thioune, H. Fessi, J. P. Devissaguet and F. Puisieux. Application of an original process for obtaining colloidal dispersions of some coating polymers. Preparation, characterization, industrial scale-up. Drug Dev. Ind. Pharm. 21:229-241 (1995).
11. H. Fessi, J. P. Devissaguet, F. Puisieux and C. Thies. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US. Pat. 5,118,528 (1992).